Next Article in Journal
Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo
Previous Article in Journal
Yield-Related QTL Clusters and the Potential Candidate Genes in Two Wheat DH Populations
Previous Article in Special Issue
8-Hydroxyquinoline-Amino Acid Hybrids and Their Half-Sandwich Rh and Ru Complexes: Synthesis, Anticancer Activities, Solution Chemistry and Interaction with Biomolecules
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 21
10.3390/ijms222111935
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

KYNA Derivatives with Modified Skeleton; Hydroxyquinolines with Potential Neuroprotective Effect †

by
Bálint Lőrinczi
1,2 and
István Szatmári
1,2,3,*
1
Institute of Pharmaceutical Chemistry, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary
2
Institute of Pharmaceutical Chemistry, Interdisciplinary Excellence Center, University of Szeged, H-6720 Szeged, Hungary
3
MTA-SZTE Stereochemistry Research Group, Hungarian Academy of Sciences, Eötvös u. 6, H-6720 Szeged, Hungary
*
Author to whom correspondence should be addressed.
†
This article is dedicated to the memory of Prof. Dr. Ferenc Fülöp, supervisor, former research group leader and institute head.
Int. J. Mol. Sci. 2021, 22(21), 11935; https://doi.org/10.3390/ijms222111935
Submission received: 28 September 2021 / Revised: 29 October 2021 / Accepted: 29 October 2021 / Published: 3 November 2021
(This article belongs to the Special Issue Synthesis and Transformations of Bioactive Hydroxyquinolines)
Browse Figures
Versions Notes

Abstract

:
Kynurenic acid (KYNA) is an endogenous neuroprotective agent of increasing importance. Several derivatives have already been synthesized, bearing an abundance of functional groups attached to the main skeleton in different positions. Several of these compounds have already been tested in biological evaluations, with several of them targeting the same receptors and biological effects as KYNA. However, these modified compounds build upon the unmodified KYNA skeleton leaving a possible route for the synthesis of new, potentially neuroprotective derivatives with heteroatom-containing ring systems. The aim of this review is to summarize the syntheses of KYNA derivatives with altered skeletons and to pinpoint an appealing transformation for future medicinal lead molecules.

Graphical Abstract

1. Introduction

KYNA (kynurenic acid) is an endogenous product of the tryptophan (TRP) metabolism, a pathway known to be responsible for the production of nicotinamide adenine dinucleotide (NAD) and NAD phosphate [1,2]. In this pathway, TRP is converted into various compounds, including L-kynurenine, which can be metabolized in two separate ways. One furnishes KYNA, whereas the other gives 3-hydroxykynurenine and quinolinic acid, the precursors of NAD [3,4].
Among the important features of KYNA, it is one of few known endogenous excitatory amino acid receptor blockers with a broad spectrum of antagonistic properties in supraphysiological concentrations. It is well established that KYNA has a high affinity towards N-methyl-D-aspartate (NMDA) receptors. Moreover, it has recently been disclosed that KYNA shows an even higher affinity towards positive modulatory binding sites at α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor [5].
Since KYNA is a neuroprotective agent able to prevent neuronal loss following excitotoxic, ischemia-induced, and infectious neuronal injuries [6,7], there has recently been increasing interest in the synthesis and pharmacological studies of KYNA derivatives. The substitution of KYNA at positions 5–8 was achieved by starting from the corresponding aniline via the modified Conrad–Limpach method [8,9,10]. The hydroxy group at position four was transformed to ether [10,11,12] or amine functions [13,14,15], while the carboxylic function at position two was mostly modified into the corresponding esters [10,11,12] or amides [16,17,18,19,20,21].
These modifications on the 4-hydroxyquinoline-2-carboxylic acid skeleton can either be (i) additions or modifications of functional groups at different positions or (ii) modifications in the benzo-fused 4-oxo-1,4-dihydropyridine-2-carboxylic acid skeleton itself. The latter can also be grouped into two distinct subgroups: the exchange of carbons to heteroatoms or the change of B ring size. While aspect (i) was already reviewed in 2009 [21], modifications on the B ring have not yet been collected. The aim of this review is to summarize the syntheses of KYNA derivatives modified at the B ring that either contain a heteroatom in the B ring and/or have a different ring size (Figure 1). In the future, these compounds may provide a basis for the synthesis of new KYNA derivatives and thus a variety of candidates for medicinal use.
With this in mind, the secondary aim of this review is to collect new substitution reactions carried out on the kynurenic acid skeleton. These new modifications may provide possibilities to improve pharmacological characteristics of the base compound, such as water solubility, blood-brain-barrier penetration and/or biological effects.
The synthesis of modified quinoline structures has a wide variety of possible methods [22]. However, with the 2-carboxylic and 4-oxo functions taken into consideration, the possible routes are narrowed down to a small range of nucleophilic substitutions or additions followed by intramolecular ring closure. Since the syntheses, from this aspect, differ only in a few cases, they have been categorized on the basis of the type and position of the heteroatom in the modified skeletons.

2. Synthesis of Functionalized and Heteroatom Containing KYNA Derivatives

2.1. Nitrogen-Containing Ring Systems

2.1.1. Pyridine- and Pyrimidine-Fused Ring Systems

A possible route for the preparation of functionalized quinoline structures is the Conrad–Limpach synthesis. During the procedure described by Max Conrad and Leonhard Limpach, an aniline is reacted with β-keto esters to form an intermediate Schiff-base. In the second step, this intermediate undergoes a thermal intramolecular ring closure yielding the final quinolone derivative [23,24,25]. As the synthesis of the intermediate can be achieved with several methods, variations of the reaction using different aniline derivatives or electrophiles to synthesize the intermediate have been disclosed.
One of the first reviews on the synthesis of KYNA derivatives bearing modified B rings (Figure 2. I) was published by Williamson et al. The reaction starting out from aniline derivative 1a used ethyl ethoxalylacetate as β-keto ester, yielding intermediate 2a. Then the product was stirred in boiling diphenyl ether (Ph2O) to achieve ring closure yielding 1,5-naphthyridine derivative 3a (Scheme 1, Table 1) [26].
The same method was utilized 50 years later by Nakamoto et al. [27] and Feng et al. [28] in two distinct patents to synthesize the intermediates of 3b by using either diethyl oxalacetate or its alkali salt, sodium (Z)-1,4-diethoxy-1,4-dioxobut-2-en-2-olate, respectively. The synthesized compounds were later transformed to potential antifungal [27] and antimalarial [29] or potential farnesoid X receptor modulators (Scheme 1 and Table 1) [28,30].
In the case of the synthesis of 1,6-naphthyridine derivatives, the method presented in the literature [31] involves a procedure different from the one described by Conrad and Limpach. Pyridine with an active α-methyl function (4), which can be regarded as an acetophenone derivative [32], is reacted with dimethyl oxalate in the presence of excess MeONa needed to shift the reaction toward the ring closure (Scheme 2).
Regarding the synthesis of 1,7-naphthyridine derivatives, the literature is scarce: only two patents mention these compounds. In both cases, the derivatives were used to broaden the 4-hydroxyquinoline-2-carboxylic acid scaffold of the final bioactive compound with an additional heteroatom-containing skeleton (8, 10, 11, 13, Scheme 3 and Scheme 4) [33,34]. However, the patents neither described the synthesis of the naphthyridine skeleton nor cited an appropriate reference.
The synthesis of 1,8-naphthyridine, containing a carboxylic function at position C-2 and a hydroxy function at position C-4, was first carried out by Weiss et al. [35]. The reaction is a perfect example of the Conrad–Limpach procedure [23,24,25] using a substituted β-keto ester. For the formation of the Schiff base, α-ethoxalylpropionate (a β-keto ester) was applied, yielding 16; however, its isolation in high purity was unsuccessful (Scheme 5).
The modification used in the synthesis of many KYNA derivatives [36] was also applied for the synthesis of 1,8-naphthyridine derivatives. This method involves the use of acetylene derivatives for the synthesis of enamine intermediates through Michael addition. Tonetti et al. [37] utilized this method to synthesize 19 by applying dimethylacetylenedicarboxylate (DMAD) as an electrophilic reagent. However, the precise conditions of the synthesis are unclear, as the original paper could not be found, and the reaction scheme was put forward based on the information gathered from Chemical Abstracts (Scheme 6).
However, judging from the work of Huc et al., it is safe to conclude that the reaction depicted in Scheme 7 is correct, since the research group managed to synthesize the same compound from the same starting materials (Scheme 7) [38]. Derivative 19 was later used to create oligomers that were investigated in the hope of finding foldamers with a chemical space as vast as their aliphatic counterparts (namely, α-peptides) [39,40,41,42].
The same method was applied by Dohmori et al. [43] during the synthesis of different potentially antimicrobial agents (against Trichomonas vaginalis). Pyrrolidine-substituted 1,8-naphthyridine 23 was synthesized using functionalized aminopyridine 21 and DMAD, albeit with a low yield of 11%. Nevertheless, it further supports the idea that these compounds can be synthesized with this modified Conrad–Limpach procedure (Scheme 8).
The use of DMAD to carry out the Michael addition and, subsequently, the synthesis of different pyrimidine-containing skeletons have also been investigated. The first method published describes the synthesis of pyrido [3,2-d]pyrimidine skeleton [44]. This method was later optimized by Rosowsky et al. by decreasing the reaction time of the intramolecular ring closure from 45 min to a reaction time as short as 3 min (Scheme 9) [45]. The method was later cited by patents for the synthesis of compounds exhibiting PI3K inhibitory activities [46].
The synthesis of the pyrido[2,3-d]pyrimidine skeleton has also been described; however, in the first publication, it was only mentioned as a desired product. The research group tried to apply the same Michael addition with DMAD. However, the reaction yielded the C-5 carbonylated derivative of 6-aminouracil (28, Scheme 10) [47]. Sakaguchi et al. tried to achieve the ring closure by changing N,N-dimethylformamide (DMF) to MeOH. Still, both at room temperature and under reflux conditions, the formation of the same maleate intermediate 29 was observed. Subsequently, it was transformed in either DMF or MeOH under reflux to 2-oxo-4-carboxylic acid derivative 30. However, in MeOH, the formation of a minimal amount of the 4-oxo derivative 31 also took place. This observation, in combination with the fact that solvents used for other Conrad–Limpach ring closure steps [Dowtherm A, 1,2-dichlorobenzene (DCB)] were not investigated, indicates that the synthesis with a better yield may be possible (Scheme 10) [48].
Dorokhov et al. used their method for 1,6-naphthyridine 6 [32] to synthesize a wide variety of pyrimidine analogues (33a,b, 34a–g) as well (Scheme 11) [49].

2.1.2. N-Bridgehead Annulations

For the synthesis of 4H-pyrido[1,2-a]-pyrimidin-4-one skeleton (Figure 2. II), several methods have been described. Earlier reports include the reaction of 2-aminpyridine with different reagents under varied conditions ranging from reactions at 250 °C using Meldrum’s acid [50] through reactions in AcOH (under reflux conditions) [51] or with the use of metal catalysts [52] to milder reactions in ethanol at reflux temperature [53]. However, the synthesis of quinoline compounds bearing both the same bridgehead nitrogen and the 4-oxo and 2-carboxylic functions required different conditions. In this subsection, the methods on the synthesis of the specific skeleton until now are collected.
As a straightforward approach, the Conrad–Limpach procedure can also be applied to synthesize the required derivatives. Diethyl 2-methyl-3-oxosuccinate, as a functionalized β-keto ester, was used by Jaenicke et al. [54] along with bismuth trichloride as a catalyst to synthesize KYNA analog 36, methyl-substituted at C-3 containing bridgehead nitrogen (Scheme 12). Regarding catalysts, the reaction showed high selectivity toward bismuth trichloride compared to other salts, such as zinc chloride or iridium chloride.
It has been shown in two articles that the synthesis can also be carried out without the use of a toxic metal catalyst. Starting from the same β-keto ester, the synthesis of both 36 and the 6-bromo-substituted derivative 38 could be achieved (Scheme 13) [55,56]. However, the inaccurate description of the methods (no given w/w% and mol% of TsOH-SiO2 catalyst) and the lower yields overshadow the results.
Similar to the synthesis of pyridine-fused derivatives, the β-keto ester electrophile can be replaced by other electron-deficient reagents, such as DMAD. One of the reactions described used the acetylene derivative in water. The reaction carried out at room temperature yielded the unsubstituted N-bridgehead derivative 40 in 6 h (Scheme 14) [57]. This procedure was later applied in a patent to create derivatives inhibiting MeTTL3 activity, and in this way, also inhibiting proliferative disorders, such as cancer, autoimmune, infectious or inflammatory diseases [58].
A similar procedure was used by Summa et al. [59,60] to synthesize 3-hydroxy-containing 9aH-pyrido[1,2-a]pyrimidine derivatives (Scheme 15). Based on the Conrad–Limpach procedures using DMAD as described in previous paragraphs, it is expected that the first step would involve the enamine formation of the acetylene and the amino group. However, based on their previous experiences with the synthesis of hydroxypyrimidinones, the formation of an O-adduct intermediate was expected. This could possibly be a 2-aminopyridine-N-oxide regarded as the tautomer of amidoxime. These derivatives are known to react with DMAD to form O-adducts (vinylhydroxylamines) [61,62,63,64,65]. The subsequent rearrangement/cyclization of 42a,b took place in o-xylene under reflux. However, the isolation of the product was not described since it was further transformed without isolation into its pivalate derivative (43a) in order to facilitate its purification. The procedure was successfully broadened to other aminopyridine derivatives as well, with N-oxidation of the aminopyridines. It is interesting to mention that in the case of 43c, the described final synthesis using p-toluenesulfonic acid (pTsOH) as a catalyst was performed in a single step, providing the lowest yield.
Furthermore, in addition to DMAD, the synthesis of the same C-3 hydroxy-functionalized compounds can be achieved through the use of a different electrophile, namely, dimethyl diacetoxyfumarate. Upon reacting with substituted 2-aminopyridines, it yields 2-hydroxy-pyrido[1,2-a]pyrimidin-4-on-2-carboxylic acid derivatives (45a,b, Scheme 16) [66]. The method was later applied for the synthesis of different HIV-1 integrase inhibitors [67,68,69].
In continuing the discussion of reactions utilizing acetylenes to yield the desired pyrido[1,2-a]pyrimidin skeleton, DMAD can also be reacted with nucleophiles derived from unique compounds. An interesting alternative method was investigated by Rees et al. using 1,2,4-triazolo[4,3-a]pyridine as the nucleophile (Scheme 17) [70]. Among other reaction routes yielding different products, DMAD can react with the N-1 atom of the triazole ring, yielding intermediate 47a delivering 48 through a ring-opening and subsequent intramolecular ring-closure.
Even though previous methods described above give possibilities for the synthesis of C-3-substituted derivatives, further functionalization can be achieved through the method reported by Ackermann et al. [71]. Starting from 2-pyridylhydrazone 49 and alkyne 50a,b, manganese-catalyzed carbonylative annulations yielding compounds 36 and 51 were carried out (Scheme 18). The method was mainly used for the synthesis of non-carboxylic derivatives; however, judging from the number of available acetylene derivatives, this reaction may provide a useful approach to synthesize new, C-3 functionalized N-bridgehead KYNA derivatives.
One of the first publications regarding the synthesis of the pyrido[1,2-a]-pyrimidine skeleton was published in 1969 by Sturm et al. [72]. An azide derivative, a special nucleophile, was used as starting compound upon reacting with either dimethyl fumarate (64% product yield) or dimethyl maleate (59% yield). The following steps were proposed for a possible mechanism. First, tautomer 52b reacts with one of the electrophiles through a Diels–Alder type forming a 5-membered ring. In subsequent ring-opening and elimination of N2, enamine intermediate 39 is formed, which, after a thermally driven ring closure, gives 40 as the final product (Scheme 19). The reaction between aminopyridine and acetylenedicarboxylic acid esters resulting in the same enamine (39) and giving the same product (40) after cyclization at 140 °C was also mentioned. However, neither a synthesis description nor a literature reference were included.
The use of malonic acid derivatives was also applied to synthesize derivatives bearing C-3 substitutions. However, this method requires further modifications since ring closure yields only 2-hydroxy derivative 54 that needs to be oxidized (Scheme 20) [73]. Even though the procedure itself is not as elegant as the previous ones, the use of functionalized anilines and malonic acids may yield a wide range of derivatives.
It is worth mentioning that the formation of the pyridine-fused pyrimidine skeleton has also been observed during the pyrolysis of an isoxazoline-substituted isoquinoline (59). The research group investigated the photolysis of different isoxazoline-substituted derivatives. When the photolysis of 59 was changed to pyrolysis in a scale-up study, the formation of 61 was observed (Scheme 21) [74].
Six-membered heterocycles containing more heteroatoms have reduced reactivity toward electrophiles. As a consequence, during the synthesis of KYNA skeletons with pyridazine, pyrimidine or pyrazine moieties, aniline starting materials may require further modifications. One such modified method applied by Mátyus et al. uses DMAD, and the accompanying aminopyridazine was substituted with electron-donating groups (EDG). However, besides electron donation, further factors may be present, as ring closure led to the formation of the desired pyrimido[1,2-b]pyridazin-2-one derivative only in the case of the hydroxy-substituted starting compound (64a). The morpholino group yielded 2-oxo-4-carboxylate analogues, similar to the chloro-substituted derivative (64b,c, Scheme 22) [75,76]. The research group also noted this difference as an anomaly, based on previous work [77]. These pieces of information and results with electron-density calculations support the conclusion that the favored reaction would be a nucleophilic addition on the C-3 of DMAD.
Koomen et al. [78] also used DMAD to synthesize adenosine derivatives bearing fluorescent attributes (Scheme 23). The starting 2′-deoxyadenosine compound 65 can be considered to be an imidazole-fused 6-aminopyrimidine. As previously mentioned, pyrimidine derivatives should be less reactive and thus unwilling to undergo the Michael addition; however, the imidazole ring may induce an excess of electrons of the pyrimidine ring, thus promoting the reaction.
The work of Liu et al. [79] also seems to support the hypothesis that an electron-donating substituent favors the Michael addition. The synthesis of a special tetracyclic quinoline derivative [4(1H)-oxopyrimido[1,2-a]perimidine-2-carboxylate, 68] was carried out starting from 2-aminoperimidine; hence, that can be considered to be 2-aminopyrimidine fused with naphthalene. Compared to the imidazole ring discussed previously, the naphthalene ring has a more prominent electron-donating quality. Consequently, the reaction could be carried out in MeOH (Scheme 24).
The work of Jain et al. can be regarded as a further development of the study by Sturm et al. described in Scheme 19, except that it was implemented in the synthesis of bridgehead derivatives [80]. Through a different procedure, an azide intermediate was generated in both studies and was then reacted further with a fumaric acid ester (in this case, diethyl fumarate, DEF). Besides the hypothesized steps described by Sturm et al., an alternative route has also been proposed. First, the decomposition of the azide function takes place, and then a subsequent DEF attack provides an aziridine ring that opens up to give the enamine intermediates 71a–e (Scheme 25).

2.1.3. Five-Membered B-Ring Derivatives

Since five-membered heterocyclic compounds have an excess of electrons, the modified Conrad–Limpach procedure applying DMAD or DEAD (diethyl acetylenedicarboxylate) for the intermediate formation and subsequent ring closure can be easily carried out. Both pyrrolo[2,3-b]pyridine and pyrrolo[3,2-b]pyridine ring systems (Figure 2. III) have been synthesized in a similar way. Grinev et al. used the potassium salt of 3-aminoindole-2-carboxylic acid in glacial acetic acid yielding 3-aminoindole in situ that subsequently reacted with DEAD (Scheme 26) [81]. The reaction yields δ-carbolines 76a–c, similar to the reactions described by Guyot et al. reporting the synthesis of α-carboline derivatives 79 (Scheme 27) [82].
It is interesting to note that in both cases, likely as a consequence of the high nucleophilicity of indole, the formation of side-products was also reported. In the synthesis of δ-carbolines, pentacyclic aromatic compounds appeared bearing an additional indole structure. In the case of α-carboline derivatives, in turn, Guyot et al. used N-methyl-2-aminoindole to presumably inhibit the formation of bridge-head nitrogen-containing derivatives. It was not directly specified by Guyot et al. whether it was for this reason. Nevertheless, in the following paragraphs, they described the synthesis of derivatives, where the ring closure takes place at the unsubstituted N-1 atom.
The same Conrad–Limpach procedure can also be used for the synthesis of the pyrrolo[3,4-b]pyridine skeleton. Silva et al. prepared a tetraphenylporphin (tPorphin) compound containing the pyridine-2-carboxylic acid moiety fused to one of the pyrrole rings of the porphin skeleton (82a,b, Scheme 28) [83].

2.2. Sulfur-Containing Ring Systems

Both six- and five-membered derivatives (Figure 3. I and II) have been synthesized. Kitao et al. used a modified Conrad–Limpach procedure, utilizing DMAD to form enamine intermediates (84a–c); ring formation was carried out in Ph2O (Scheme 29) [84].
Baron et al. fabricated a wide variety of excitatory amino acid antagonists with the six-membered B ring of KYNA changed to a five-membered sulfur-containing ring. The synthesis of these compounds is similar to that of the six-membered skeleton, utilizing DMAD or DEAD in the first step with the corresponding aminothiophenes (86,89). The subsequent intramolecular ring closure was carried out in Ph2O, nujol or polyphosphoric acid (Scheme 30) [85]. Unfortunately, no yields have been published for compounds 88a,b, 92a,b, 93a,b.
Although the method described in Scheme 30 has the most detailed description, it is not the only one. The synthesis of a thieno[3,2-b]pyridine system was already published earlier. Here, similar to the δ-carboline derivatives [78], DEAD was used, yielding the thieno analog (95) of δ-carboline derivative 76b (Scheme 31) [86].
The thieno[3,4-b]pyridine skeleton was already mentioned earlier. However, in this work, the synthesis yield was not reported (Scheme 32) [87].

2.3. Oxygen-Containing Ring Systems

Regarding pyrano ring systems (Figure 4. I and II), it must be emphasized that, contrary to nitrogen-bearing systems, the aromaticity of the compound is lost. Whereas the procedures described in the following paragraphs indicate that the efficiency of the synthesis is not affected, the potential biological activity may vary substantially in comparison with KYNA.
Kitao et al. based their procedure for the thiopyrano derivatives [81] on the work of Strandtmann et al. [88], who synthesized 1,5-dihydro-4,10-dioxobenzopyranopyridine-2-carboxylic acid derivatives 101a–c (Scheme 33).
Dorokhov et al., besides synthesizing the pyridine- and pyrimidine-fused derivatives with the use of acetophenones [31,32], also achieved the synthesis of pyranone derivatives. Pyranones 102a–c bearing the crucial active α-methyl function, similar to the ones used for pyridine- and pyrimidine-fused derivatives synthesized previously, were reacted with diethyl oxalate in the presence of sodium ethoxide (Scheme 34) [89].
The method used by Strandtmann et al. in the synthesis of benzopyrano[2,3-b]pyridine derivatives mentioned above was extended by the research group to synthesize benzopyrano[3,4-b]pyridine derivatives (106a–c, Scheme 35) [88]. The triazol derivatives of these compounds have been patented for their possible useful application in allergic manifestations such as bronchial asthma, hay fever, etc. [90].
Regarding the furan-fused 4-oxopyridine-2-carboxylic acid derivatives, the only synthesis mentioned describes a procedure similar to that applied in the synthesis of δ-carbolines reported earlier [82]. Using a potassium salt of 3-aminobenzofuran-2-carboxylic acid (107) and DMAD, compound 108, the furan analog of δ-carboline 76b could be synthesized (Scheme 36) [91].

2.4. New Aspects on the Synthesis of KYNA Derivatives

The aforementioned modified Conrad–Limpach procedure, applying DEAD and an aniline, has already been applied in the synthesis of KYNA [36] and several of its B-ring substituted derivatives [8,9,10].
The synthesis applying this kind of C–L has recently been optimized by Szatmári et al. by applying two steps: (i) after the formation of enamine 110a, column chromatography was used to purify the intermediate; (ii) Ph2O was replaced by DCB, which has a lower boiling point (180 °C) allowing an easier work-up procedure (Scheme 37) [92].
The synthesis of the methyl ester analogs of 114a–c has already been described [93,94]; however, no yields or exact synthetic procedures were detailed. Szatmári et al. successfully carried out the synthesis of compounds 114a–c, applying the before mentioned optimizations, reaching higher yields [95]. Furthermore, based on the work of Sutherland et al. [96], p-TsOH as a catalyst was investigated in a one-pot version of the Conrad–Limpach procedure applying microwave irradiation (Scheme 38) [95]. The synthesis provided the appropriate hydroxy derivatives in increased yields with diminished maleimide formation, and the work-up could be carried out without time-consuming chromatography.

3. Mannich-Type Transformations of KYNA and Its Substituted Derivatives

3.1. C-3 Substitutions of KYNA Derivatives

Formally, KYNA can be considered to be a nitrogen-containing 1-naphthol derivative. Based upon their previous works with 1-naphthol and its N-containing analogs [97,98,99,100], Szatmári et al. successfully applied the ethyl ester of KYNA in the modified Mannich reaction (mMr) [101]. In this regard, to explore the scope and limitations of the reaction, different primary and secondary amines (acyclic and cyclic) were reacted with KYNA in the presence of formaldehyde (22% solution) in an optimized reaction condition of 1,4-dioxane as solvent under reflux conditions with a 5 h reaction time. The synthesis all yielded the C-3 aminoalkylated kynurenic acid derivatives 118-126 (Scheme 39, Table 2).
To test the effect of substituents at positions 5, 6, 7 or 8 on the mMr, derivatives 111b–e were reacted with morpholine as a representative secondary cyclic amine in the presence of formaldehyde. Reactions were carried out under the optimized reaction conditions, concluding that aryl/alkyl substituents at position 6 or 8 and the halogen at position 5 or 7 have no significant influence on the aminoalkylation at C-3 (Scheme 40, 127–130).

3.2. Aminoalkylations of Hydroxy-KYNA Derivatives

Regarding the 1-naphthol analogy of KYNA, the B-ring substituted derivatives show possibilities for further fascinating mMr transformations. Compounds 114c, 131 through their analogy with 1-naphthol and 114a,b through their 2-naphthol analogy (Figure 5), offer new possible reaction routes for the aminoalkylation.

3.2.1. Derivatives with Structural Similarities to 1-Napthol

Hydroxylated KYNA derivatives bearing the secondary hydroxy function at position 5 or 8 show a second 1-napthol similarity. In this case, the aminoalkylations can be expected to first undergo it in position 6 or 7, respectively, as these positions can both be regarded as the C-2 and, consequently, the most reactive position of a 1-napthol skeleton, as well as the sterically-less hindered position of the KYNA skeleton. However, this substitution route was observed by Szatmári et al. only in the case of compound 114c, the reactions first yielding 132, and subsequently 133. The morpholinomethylation in the case of the 8-hydroxy derivative (131) first took place at C-3, yielding 134 and only after that at C-7 (Scheme 40, 135) [95].
In both cases, DFT calculations were carried out to support the observed results, showing that the reason behind the sluggish and irregular reactivity of 131 might be due to its low HOMO energy level.

3.2.2. Derivatives with Structural Similarities to 2-Napthol

In the case of the 6- and 7-hydroxykynurenic acids (114a,b), a similarity between the skeleton and 2-naphthol can be observed, implicating that the aminoalkylations may take place in position 5 or 7, respectively. After performing the reactions, it has been observed that only compound 114b shows the expected reactivity with the morpholinomethyl function first forming at position C-8 (138) and subsequently in position C-3 (Scheme 41, 139). In the case of compound 114a, the reaction first led to the formation of the C-3 substituted derivative and later to the formation of the disubstituted derivative (136 and 137). This unexpected reactivity was later investigated by DFT calculation disclosing HOMO delocalization and local NBO charges for the corresponding anion pairs theorized to form during the reaction. These calculations were in line with the experimental results implying that in the case of 114a, despite the similarity to 2-naphthol, the additional functional groups and heteroatom in the ring-system may override the reactivity expected from the sterically-less hindered 2-naphthol skeleton, resulting in the formation of 136 as a primary product [95].

4. Conclusions

Kynurenic acid derivatives with a modified B-ring skeleton represent an interesting alternative for the synthesis of new KYNA analogs. Most of the compounds discussed have already been synthesized with the aim of biological use, such as antiviral, antimicrobial, antiallergic or antitumor effects; however, only a fraction of them have been tested for KYNA-like effects. The primary aim of this review was to summarize the procedures used for the synthesis of KYNA derivatives. These syntheses, combined with the second aim of the review—transformations, facilitating blood-brain-barrier penetration—may pave the way for future pharmaceutical chemistry concerning KYNA derivatives.
Summarizing the procedures used for the synthesis of B-ring modified KYNA derivatives, they build upon the reaction between a nucleophile (heteroatom-containing aniline/five-membered aromatic compound with an amine function) and an electrophile [β-keto ester/dicarboxylic alkyne (DEAD or DMAD)]. Based on the electrophiles, the reactions can be categorized as Conrad–Limpach (using β-keto esters) and modified Conrad–Limpach (using DEAD or DMAD) procedures.
While the unmodified procedure may give way for C-3 substitution of the KYNA skeleton without further transformations needed, the modified Conrad–Limpach procedure, compared to the prior, has the advantage of a cheaper electrophile and, combined with the recent optimization steps or one-pot reaction set-up may provide a more cost-efficient synthesis.
As KYNA is mainly known in the literature for its neuroprotective effect, the modified Mannich reaction, resulting in derivatives bearing one or more tertiary nitrogen and thus having better blood-brain-barrier penetration, rises as a possible further transformation. As KYNA and some of its derivatives can easily undergo this reaction, it is safe to hypothesize that the B-ring modified derivatives that can be fabricated with the procedures summarized in this review can also undergo the reaction and may provide potentially neuroprotective compounds.

Author Contributions

Conceptualization, I.S.; investigation, B.L.; writing—original draft preparation, B.L.; writing—review and editing, I.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

The authors’ thanks are due to the Hungarian Research Foundation (OTKA No. K-138871); the Ministry of National Economy, National Research Development and Innovation Office [GINOP-2.3.2-15-2016-00034]; the Ministry of Human Capacities, Hungary grant, TKP-2020 and to the Gedeon Richter Plc. Centenarial Foundation.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

AcetonitrileMeCN
Blood-brain barrierBBB
1,2-DichlorobenzeneDCB
Diethylacetylene dicarboxylate DEAD
Diethyl fumarateDEF
N,N′-DiisopropylcarbodiimideDIC
Dimethylacetylene dicarboxylateDMAD
N,N-Dimethylformamide DMF
Diphenyl etherPh2O
1,3-Bis(diphenylphosphino)propanedppp
Electron-donating groupsEDG
1-Hydroxybenzotriazole hydrate HOBt
Nicotinamide adenine dinucleotideNAD
Modified Mannich reaction mMr
Polyphosphoric acidPPA
TetraphenylporphintPorphin
TNF-stimulated gene 6 proteinTSG-6
p-Toluenesulfonic acidpTsOH
TriethylamineTEA
Tryptophan TRP
Tumor necrosis factor alphaTNF-α

References

  1. Rózsa, E.; Robotka, H.; Vécsei, L.; Toldi, J. The Janus-face kynurenic acid. J. Neural Transm. 2008, 115, 1087–1091. [Google Scholar] [CrossRef]
  2. Stone, T.W. Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin. Inv. Drug. 2001, 10, 633–645. [Google Scholar] [CrossRef] [PubMed]
  3. Németh, H.; Toldi, J.; Vécsei, L. Role of kynurenines in the central and peripheral nervous systems. Curr. Neurovasc. Res. 2005, 2, 249–260. [Google Scholar] [CrossRef] [PubMed]
  4. Németh, H.; Toldi, J.; Vécsei, L. Kynurenines, Parkinson’s disease and other neurodegenerative disorders: Preclinical and clinical studies. J. Neural Transm. Supp. 2006, 70, 285–304. [Google Scholar]
  5. Sas, K.; Robotka, H.; Toldi, J.; Vécsei, L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 2007, 257, 221–239. [Google Scholar] [CrossRef] [PubMed]
  6. Gigler, G.; Szénási, G.; Simó, A.; Lévay, G.; Hársing, L.G., Jr.; Sas, K.; Vécsei, L.; Toldi, J. Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur. J. Pharmacol. 2007, 564, 116–122. [Google Scholar] [CrossRef] [PubMed]
  7. Luchowska, E.; Luchowski, P.; Sarnowska, A.; Wielosz, M.; Turski, W.A.; Urbańska, E.M. Endogenous level of kynurenic acid and activities of kynurenine aminotransferases following transient global ischemia in the gerbil hippocampus. Pol. J. Pharmacol. 2003, 55, 443–447. [Google Scholar] [PubMed]
  8. Harrison, B.L.; Baron, B.M.; Cousino, D.M.; McDonald, I.A. 4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: New antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate (NMDA) receptor complex. J. Med. Chem. 1990, 33, 3130–3132. [Google Scholar] [CrossRef] [PubMed]
  9. Edmont, D.; Rocher, R.; Plisson, C.; Chenault, J. Synthesis and evaluation of quinoline carboxyguanidines as antidiabetic agents. Bioorg. Med. Chem. Lett. 2000, 16, 1831–1834. [Google Scholar] [CrossRef]
  10. Bonina, F.P.; Arenare, L.; Ippolito, R.; Boatto, G.; Battaglia, G.; Bruno, V.; De Caprariis, P. Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs. Int. J. Pharm. 2000, 202, 79–88. [Google Scholar] [CrossRef]
  11. Manfredini, S.; Pavan, B.; Vertuani, S.; Scaglianti, M.; Compagnone, D.; Biondi, C.; Scatturin, A.; Tanganelli, S.; Ferraro, L.; Prasad, P.; et al. Design, synthesis and activity of ascorbic acid prodrugs of nipecotic, kynurenic and diclophenamic acids, liable to increase neurotropic activity. J. Med. Chem. 2002, 45, 559–562. [Google Scholar] [CrossRef] [PubMed]
  12. Manfredini, S.; Vertuani, S.; Pavan, B.; Vitali, F.; Scaglianti, M.; Bortolotti, F.; Biondi, C.; Scatturin, A.; Prasad, P.; Dalpiaz, A. Design, synthesis and in vitro evaluation on HRPE cells of ascorbic and 6-bromoascorbic acid conjugates with neuroactive molecules. Bioorgan. Med. Chem. 2004, 12, 5453–5463. [Google Scholar] [CrossRef]
  13. Yielding, K.L.; Nichols, A.C. Anticonvulsant activity of antagonists for the NMDA-associated glycine binding site. Mol. Chem. Neuropathol. 1993, 19, 269–282. [Google Scholar]
  14. Stone, T.W. Inhibitors of the kynurenine pathway. Eur. J. Med. Chem. 2000, 35, 179–186. [Google Scholar] [CrossRef]
  15. Nichols, A.C.; Yielding, K.L. Anticonvulsant activity of 4-urea-5,7-dichlorokynurenic acid derivatives that are antagonists at the NMDA-associated glycine binding site. Mol. Chem. Neuropathol. 1998, 35, 1–12. [Google Scholar] [CrossRef] [PubMed]
  16. Füvesi, J.; Somlai, C.; Németh, H.; Varga, H.; Kis, Z.; Farkas, T.; Károly, N.; Dobszay, M.; Penke, Z.; Penke, B.; et al. Comparative study on the effects of kynurenic acid and glucosamine-kynurenic acid. Pharmacol. Biochem. Behav. 2004, 77, 95–102. [Google Scholar] [CrossRef]
  17. Zhang, L.; Sun, F.; Li, Y.; Sun, X.; Liu, X.; Huang, Y.; Zhang, L.H.; Ye, X.S.; Xiao, J. Rapid Synthesis of Iminosugar Derivatives for Cell-Based In Situ Screening: Discovery of “Hit” Compounds with Anticancer Activity. ChemMedChem 2007, 2, 1594–1597. [Google Scholar] [CrossRef]
  18. Brik, A.; Lin, Y.C.; Elder, J.; Wong, C.H. A quick diversity-oriented amide forming reaction coupled with in situ screening as an approach to identify optimal p-subsite residues of HIV-1 protease inhibitors. Chem. Biol. 2002, 9, 891–896. [Google Scholar] [CrossRef] [Green Version]
  19. Tossi, A.; Benedetti, F.; Norbedo, S.; Skrbec, D.; Berti, F.; Romeo, D. Small hydroxyethylene-based peptidomimetics inhibiting both HIV-1 and C. albicans aspartic proteases. Bioorg. Med. Chem. 2003, 11, 4719–4727. [Google Scholar] [CrossRef] [PubMed]
  20. Knyihár-Csillik, E.; Mihály, A.; Krisztin-Péva, B.; Robotka, H.; Szatmári, I.; Fülöp, F.; Toldi, J.; Csillik, B.; Vécsei, L. The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: Comparative studies of the effects of SZR-72 and kynurenic acid. Neurosci. Res. 2008, 61, 429–432. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Fülöp, F.; Szatmári, I.; Vámos, E.; Zádori, D.; Toldi, J.; Vécsei, L. Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr. Med. Chem. 2009, 16, 4828–4842. [Google Scholar] [CrossRef] [Green Version]
  22. Sako, M. Category 2, Hetarenes and Related Ring Systems; Yamamoto, Y., Shinkai, I., Eds.; Product Class. 19: Pyridopyrimidines; Thieme Verlagsgruppe: Stuttgart, Germany; New York, NY, USA; New Delhi, India, 2004; pp. 1155–1267. [Google Scholar]
  23. Conrad, M.; Limpach, L. Synthesen von Chinolinderivaten mittelst Acetessigester. Ber. Dtsch. Chem. Ges. 1887, 20, 944–948. [Google Scholar] [CrossRef]
  24. Conrad, M.; Limpach, L. Ueber das γ-Oxychinaldin und dessen Derivate. Ber. Dtsch. Chem. Ges. 1887, 20, 948–959. [Google Scholar] [CrossRef] [Green Version]
  25. Hauser, C.R.; Reynolds, G.A. Reactions of β-keto esters with aromatic amines. Synthesis of 2-and-4-hydroxyquinoline derivatives. J. Am. Chem. Soc. 1948, 70, 2402–2404. [Google Scholar] [CrossRef]
  26. Goldberg, A.A.; Theobald, R.S.; Williamson, W. Derivatives of 2-alkoxy-8-amino-1:5-naphthyridines. J. Chem. Soc. 1954, 2357–2361. [Google Scholar] [CrossRef]
  27. Abe, S.; Haneda, T.; Hata, K.; Inoue, S.; Matsukura, M.; Nakamoto, K.; Tanaka, K.; Tsukada, I.; Ueda, N.; Watanabe, N. Novel Antifungal Agent Comprising Heterocyclic Compound. Patent WO2005033079A1, 14 April 2005. [Google Scholar]
  28. Carpenter, J.; Broekema, M.; Feng, J.; Liu, C.; Wang, W.; Wang, Y. Alkene Compounds as Farnesoid X Receptor Modulators. Patent WO2019089670A1, 9 May 2019. [Google Scholar]
  29. Abe, S.; Haneda, T.; Inoue, S.; Matsukura, M.; Nakamoto, K.; Sagane, K.; Tanaka, K.; Tsukada, I.; Ueda, N. Novel Antimalaria Agent Containing Heterocyclic Compound. Patent WO2006016548A1, 16 February 2006. [Google Scholar]
  30. Feng, J.; Liu, C.; Huang, Y. Alkene Spirocyclic Compounds as Farnesoid X Receptor Modulators. Patent WO2019089665A1, 9 May 2019. [Google Scholar]
  31. Vasil’ev, L.S.; Surzhikov, F.E.; Baranin, S.V.; Dorokhov, V.A. Trifluoromethyl-substituted 1,6-naphthyridines and pyrido[4,3-d]pyrimidines. Russ. Chem Bull. 2013, 62, 1255–1261. [Google Scholar] [CrossRef]
  32. Vasil’ev, L.S.; Surzhikov, F.E.; Azarevich, O.G.; Bogdanov, V.S.; Dorokhov, V.A. Synthesis of 4-hydroxy- and 3-aryl-4-amino- 2-trifluoromethylpyridines. Russ. Chem. Bull. 1996, 45, 2574–2577. [Google Scholar] [CrossRef]
  33. Andrews, M.D.; Bagal, S.K.; Gibson, K.R.; Omoto, K.; Ryckmans, T.; Skerratt, S.E.; Stupple, P.A. Pyrrolo[2,3-d]pyrimidine Derivatives as Inhibitors of Tropomyosin-Related Kinases. Patent WO2012137089A1, 11 October 2012. [Google Scholar]
  34. Andrews, M.D.; Bagal, S.K.; Gibson, K.R.; Omoto, K.; Ryckmans, T.; Skerratt, S.E.; Stupple, P.A. Pyrrolo[2,3-d]pyrimidine Tropomysin-Related Kinase Inhibitors. Patent US8846698B2, 30 September 2014. [Google Scholar]
  35. Hauser, C.R.; Weiss, M.J. Cyclization Of 2-Aminopyridine Derivatives To Form 1,8-Naphthyridines. J. Org. Chem. 1949, 14, 453–459. [Google Scholar] [CrossRef]
  36. Zhou, Y.; Li, W.; Liu, Y.; Zeng, L.; Su, W.; Zhou, M. Substituent effect of ancillary ligands on the luminescence of bis [4,6-(di-fluorophenyl)-pyridinato-N,C2′]iridium(III) complexes. Dalton Trans. 2012, 31, 9373–9381. [Google Scholar] [CrossRef]
  37. Carboni, S.; Da Settimo, A.; Bertini, D.; Ferrarini, P.L.; Livi, O.; Mori, C.; Tonetti, I. Gazz. Chim. Ital. 1972, 102, 253–264. [Google Scholar]
  38. Ferrand, Y.; Kendhale, A.M.; Garric, J.; Kauffmann, B.; Huc, I. Parallel and antiparallel triple helices of naphthyridine oligoamides. Angew. Chem. Int. Ed. 2010, 49, 1778–1781. [Google Scholar] [CrossRef] [PubMed]
  39. Mateus, P.; Chandramouli, N.; Mackereth, C.D.; Kauffmann, B.; Ferrand, Y.; Huc, I. Allosteric recognition of homomeric and heteromeric pairs of monosaccharides by a foldamer capsule. Angew. Chem. Int. Ed. 2020, 59, 5797–5805. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Gole, B.; Kauffmann, B.; Maurizot, V.; Huc, I.; Ferrand, Y. Light-controlled conformational switch of an aromatic oligoamide foldamer. Angew. Chem. Int. Ed. 2019, 58, 8063–8067. [Google Scholar] [CrossRef] [PubMed]
  41. Wang, X.; Gan, Q.; Wicher, B.; Ferrand, Y.; Huc, I. Directional threading and sliding of a dissymmetrical foldamer helix on dissymmetrical axles. Angew. Chem. Int. Ed. 2019, 58, 4205–4209. [Google Scholar] [CrossRef]
  42. Saha, S.; Kauffmann, B.; Ferrand, Y.; Huc, I. Selective encapsulation of disaccharide xylobiose by an aromatic foldamer helical capsule. Angew. Chem. Int. Ed. 2018, 57, 13542–13546. [Google Scholar] [CrossRef] [PubMed]
  43. Suzuki, N.; Kato, M.; Dohmori, R. [Synthesis of antimicrobial agents. II. Synthesis of 1,8-naphthyridine derivatives and their activities against Trichomonas vaginalis (author’s transl)]. Yakugaku Zasshi. 1979, 99, 155–164. [Google Scholar] [CrossRef] [Green Version]
  44. Srinivasan, A.; Broom, A.D. Pyridopyrimidines. 10. Nucleophilic substitutions in the pyrido[3,2-d]pyrimidine series. J. Org. Chem. 1979, 44, 435–440. [Google Scholar] [CrossRef]
  45. Rosowsky, A.; Forsch, R.A.; Queener, S.F. 2,4-Diaminopyrido[3,2-d]pyrimidine Inhibitors of Dihydrofolate Reductase from Pneumocystis carinii and Toxoplasma gondii. J. Med. Chem. 1995, 38, 2615–2620. [Google Scholar] [CrossRef]
  46. Desforges, G.; Gaillard, P.; Montagne, C.; Pomel, V.; Quattropani, A. 4-Morpholino-pyrido[3,2-d]pyrimidines. Patent WO2010037765A2, 8 April 2010. [Google Scholar]
  47. Shim, J.L.; Niess, R.; Broom, A.D. Acylation of some 6-aminouracil derivatives. J. Org. Chem. 1972, 37, 578–581. [Google Scholar] [CrossRef]
  48. Ogura, H.; Sakaguchi, M. A novel synthesis of 5-oxo- and 7-oxo-pyrido[2,3-d]pyrimidines. Chem. Lett. 1972, 1, 657–658. [Google Scholar] [CrossRef]
  49. Komkov, A.V.; Dorokhov, V.A. Simple synthesis of alkyl 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine-7-carboxylates from 5-acetyl-4-aminopyrimidines. Russ. Chem Bull. 2002, 51, 1875–1878. [Google Scholar] [CrossRef]
  50. Cassis, R.; Tapia, R.; Valderrama, A. Synthesis of 4 (1H)-quinolones by thermolysis of arylaminomethylene Meldrum’s acid derivatives. Synth. Commun. 1985, 15, 125–133. [Google Scholar] [CrossRef]
  51. Jadhav, S.B.; Fatema, S.; Patil, R.B.; Sangshetti, J.N.; Farooqui, M. Pyrido[1,2-a]pyrimidin-4-ones: Ligand-based Design, Synthesis, and Evaluation as an Anti-inflammatory Agent. J. Heterocycl. Chem. 2017, 54, 3299–3313. [Google Scholar] [CrossRef]
  52. Yang, Y.; Shu, W.-M.; Yu, S.-B.; Ni, F.; Gao, M.; Wu, A.-X. Auto-tandem catalysis: Synthesis of 4H-pyrido[1,2-a]pyrimidin-4-ones via copper-catalyzed aza-Michael addition–aerobic dehydrogenation–intramolecular amidation. Chem. Commun. 2013, 49, 1729–1731. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Bonacorso, H.G.; Righi, F.J.; Rodrigues, I.R.; Cechinel, C.A.; Costa, M.B.; Wastowski, A.D.; Martins, M.A.P.; Zanatta, N. New efficient approach for the synthesis of 2-alkyl(aryl) substituted 4H-pyrido[1,2-a]pyrimidin-4-ones. J. Heterocycl. Chem. 2006, 43, 229–233. [Google Scholar] [CrossRef]
  54. Roslan, I.I.; Lim, Q.-X.; Han, A.; Chuah, G.-K.; Jaenicke, S. Solvent-Free Synthesis of 4H-Pyrido[1,2-a]pyrimidin-4-ones Catalyzed by BiCl3: A Green Route to a Privileged Backbone. Eur. J. Org. Chem. 2015, 2351–2355. [Google Scholar] [CrossRef]
  55. Mathavan, S.; Durai Raj, A.K.; Yamajala, R.B.R.D. A Metal-free Approach for the Synthesis of Privileged 4H-pyrido[1,2-a]pyrimidin-4-one Derivatives over a Heterogeneous Catalyst. ChemistrySelect 2019, 4, 10737–10741. [Google Scholar] [CrossRef]
  56. Yu, T.; Li, N.; Wu, C.; Guan, A.; Li, Y.; Peng, Z.; He, M.; Li, J.; Gong, Z.; Huang, L.; et al. Discovery of pyridopyrimidinones as potent and orally active dual inhibitors of PI3K/mTOR. ACS Med. Chem. Lett. 2018, 9, 256–261. [Google Scholar] [CrossRef]
  57. Yan, H.; Ma, Y.; Sun, Y.; Ma, C.; Wang, Y.; Ren, X.; Huang, G. Catalyst-free synthesis of alkyl 4-oxo-4H-pyrido [1, 2-a] pyrimidine-2-carboxylate derivatives on water. Tetrahedron 2014, 70, 2761–2765. [Google Scholar] [CrossRef]
  58. Blackaby, W.; Brookfield, F.; Bubert, C.; Hardick, D.; Ridgill, M.; Shepherd, J.; Thomas, E. METTL3 Inhibitory Compounds. Patent WO2020201773A1, 8 October 2020. [Google Scholar]
  59. Kinzel, O.D.; Ball, R.G.; Donghi, M.; Maguire, C.K.; Muraglia, E.; Pesci, S.; Rowley, M.; Summa, V. 3-Hydroxy-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylates—fast access to a heterocyclic scaffold for HIV-1 integrase inhibitors. Tetrahedron Lett. 2008, 49, 6556–6558. [Google Scholar] [CrossRef]
  60. Donghi, M.; Kinzel, O.D.; Summa, V. 3-Hydroxy-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylates—A new class of HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 1930–1934. [Google Scholar] [CrossRef]
  61. Muraglia, E.; Kinzel, O.; Gardelli, C.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Nizi, E.; Orvieto, F.; Pescatore, G.; Laufer, R.; et al. Design and Synthesis of Bicyclic Pyrimidinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors. J. Med. Chem. 2008, 51, 861–874. [Google Scholar] [CrossRef] [PubMed]
  62. Kinzel, O.D.; Monteagudo, E.; Muraglia, E.; Orvieto, F.; Pescatore, G.; Rico Ferreira, M.; Rowley, M.; Summa, V. The synthesis of tetrahydropyridopyrimidones as a new scaffold for HIV-1 integrase inhibitors. Tetrahedron Lett. 2007, 48, 6552–6555. [Google Scholar] [CrossRef]
  63. Crescenzi, B.; Kinzel, O.; Muraglia, E.; Orvieto, F.; Pescatore, G.; Rowley, M.; Summa, V. Patent WO2004058757A1, 15 July 2004.
  64. Koch, U.; Attenni, B.; Malancona, S.; Colarusso, S.; Conte, I.; Di Filippo, M.; Harper, S.; Pacini, B.; Giomini, C.; Thomas, S.; et al. 2-(2-Thienyl)-5, 6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: Discovery, SAR, modeling, and mutagenesis. J. Med. Chem. 2006, 49, 1693–1707. [Google Scholar] [CrossRef]
  65. Zhong, Y.-L.; Zhou, H.; Gauthier, D.R., Jr.; Askin, D. Efficient synthesis of functionalized pyrimidones via microwave-accelerated rearrangement reaction. Tetrahedron Lett. 2006, 47, 1315–1317. [Google Scholar] [CrossRef]
  66. Tisler, M.; Zupet, R. An improved synthesis of dimethyl diacetoxyfumarate and its condensation with heterocyclic amines. Org. Prep. Proced. Int. 1990, 22, 532–534. [Google Scholar] [CrossRef]
  67. Jones, E.D.; Vandegraaff, N.; Le, G.; Choi, N.; Issa, W.; Macfarlane, K.; Thienthong, N.; Winfield, L.J.; Coates, J.A.V.; Lu, L.; et al. Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: Selection of the scaffold. Bioorg. Med. Chem. Lett. 2010, 20, 5913–5917. [Google Scholar] [CrossRef]
  68. Deadman, J.J.; Jones, E.D.; Le, G.T.; Rhodes, D.I.; Thienthong, N.; Vandegraff, N.; Winfield, L.J. Compounds Having Antiviral Properties. Patent WO2010000032A1, 7 January 2010. [Google Scholar]
  69. Le, G.; Vandegraff, N.; Rhodes, D.I.; Jones, E.D.; Coates, J.A.V.; Lu, L.; Li, X.; Yu, C.; Feng, X.; Deadman, J.J. Discovery of potent HIV integrase inhibitors active against raltegravir resistant viruses. Bioorg. Med. Chem. Lett. 2010, 20, 5013–5018. [Google Scholar] [CrossRef]
  70. Heath, D.G.; Rees, C.W. Reaction of 1,2,4-triazolo[4,3-a]pyridine with dimethyl acetylenedicarboxylate: New structures and mechanisms. J. Chem. Soc. Chem. Comm. 1982, 21, 1280–1282. [Google Scholar] [CrossRef]
  71. Liang, Y.-F.; Steinbock, R.; Münch, A.; Stalke, D.; Ackermann, L. Manganese-Catalyzed Carbonylative Annulations for Redox-Neutral Late-Stage Diversification. Angew. Chem. Int. Ed. 2018, 57, 5384–5388. [Google Scholar] [CrossRef] [PubMed]
  72. Huisgen, R.; Frauenberg, K.; Sturm, H.J. Cycloadditionen von pyridyl-und pyrimidyl-aziden. Tetrahedron Lett. 1969, 30, 2589–2594. [Google Scholar] [CrossRef]
  73. Bergnes, G.; Chabala, J.C.; Dhanak, D.; Knight, S.D.; Mcdonald, A.; Morgans, D.J.; Zhou, H.-J. Compounds, Compositions and Methods. Patent WO2004064741A2, 5 August 2004. [Google Scholar]
  74. Ang, K.H.; Cox, M.; Lawrance, W.D.; Prager, R.; Smith, J.A.; Staker, W. Triplet lifetimes, solvent, and intramolecular capture of isoxazolones. Aust. J. Chem. 2004, 57, 101–105. [Google Scholar] [CrossRef]
  75. Mátyus, P.; Ősapay, K.; Gabányi, Z.; Kasztreiner, E.; Sohár, P. Kísérletek amino-diazinok két nukleofil reakciójának kvantumkémiai értelmezésére. Kem. Kozl. 1986, 66, 203–212. [Google Scholar]
  76. Mátyus, O.; Szilágyi, G.; Kasztreiner, E.; Rabloczky, G.; Sohár, P. Some aspects of the chemistry of pyrimido[1,2-B]pyridazinones. J. Heterocycl. Chem. 1988, 25, 1535–1542. [Google Scholar] [CrossRef]
  77. Gerorge, V.M.; Khetan, K.S.; Gupta, K.R. Advances in Heterocyclic Chemistry; Keritzky, R.A., Boulton, J.A., Eds.; Academic Press: New York, NY, USA; San Francisco, CA, USA; London, UK, 1976; Volume 19, p. 280. [Google Scholar]
  78. Boer, R.F.; Petra, D.G.I.; Wanner, M.J.; Boesaart, A.; Koomen, G.J. Nucleos. Nucleot. 1995, 14, 349–352. [Google Scholar]
  79. Liu, K.-C.; Huang, H.-S. Synthesis of methyl 4 (1H)-oxopyrimido[1,2-a]perimidine-2-carboxylate. Arch. Pharm. 1988, 321, 771–772. [Google Scholar] [CrossRef]
  80. Bhagat, S.; Jain, M.; Pandey, M.K.; Saxena, P.A.; Jain, S.C. Synthesis of new bridgehead heterocycles: Pyrimido[3’,2’:3,4]-1,2,4-triazino[5,6-b]indoles. Heteroat. Chem. 2006, 17, 272–276. [Google Scholar] [CrossRef]
  81. Boyarintseva, O.N.; Kurilo, G.N.; Anisimova, O.S.; Grinev, A.N. Reaction of 3-aminoindole-2-carboxylic acids with an acetylenedicarboxylate ester. Khim. Geterotsikl. 1977, 1, 82–84. [Google Scholar]
  82. Meyer, M.; Guyot, M. Synthesis of 2-substituted indolopyridin-4-ones. Tetrahedron Lett. 1996, 37, 4931–4932. [Google Scholar] [CrossRef]
  83. Silva, A.M.G.; Castro, B.; Rangel, M.; Silva, A.M.S.; Brandão, P.; Felix, V.; Cavaleiro, J.A.S. Microwave-enhanced synthesis of novel pyridinone-fused porphyrins. Synlett 2009, 1009–1013. [Google Scholar] [CrossRef]
  84. Nakazumi, H.; Endo, T.; Nakaue, T.; Kitao, T. Synthesis of 4,10-dihydro-4,10-dioxo-1H[1]benzothiopyrano[3,2-B]pyridine and 7-oxo-7,13-dihydro[1]benzothiopyrano[2,3-b]-1,5-benzodiazepine. J. Heterocycl. Chem. 1985, 22, 89–92. [Google Scholar] [CrossRef]
  85. Baron, B.M.; Harrison, B.L. Certain Quinolines and Thienopyridines as Excitatory Amino Acid Antagonists. Patent US5026700A, 25 June 1991. [Google Scholar]
  86. Goerlitzer, K.; Kramer, C. Potential antiallergics. 3. Synthesis and transformations of 1, 4-dihydro-4-oxo-(1) benzothieno (3, 2-b) pyridine-2-carboxylic acid esters. Pharmazie 2000, 9, 645–650. [Google Scholar] [CrossRef]
  87. Barker, J.M.; Huddleston, P.R.; Jones, A.W.; Edwards, M. Thienopyridines. Part 2. Application of the Conrad−Limpach and Gould−Jacobs reactions to the synthesis of thieno[3,4-b]pyridin4(1H)-ones. J. Chem. Res. S. 1980, 1, 4–5. [Google Scholar]
  88. Connor, D.T.; Young, P.A.; Strandtmann, M. Synthesis of 4,10-dihydro-4,10-dioxo-1H-[1]-benzopyrano[3,2-b]pyridine, 4,5-Dihydro-4,5-dioxo-1H-[1]-benzopyrano[2,3–6]pyridine and 1,5-Dihydro-1,5-dioxo-4H-[1]-benzopyrano[3,4-b]pyridine derivatives from aminobenzopyrones. J. Heterocycl. Chem. 1981, 18, 697–702. [Google Scholar] [CrossRef]
  89. Dorokhov, V.A.; Vasilyev, A.V.; Baranin, S.V. Synthesis of 3-acetyl-4-amino-6-arylpyran-2-ones and ethyl 7-aryl-4,5(1H, 5H)-dioxopyrano[4,3-b]pyridine-2-carboxylates. Russ. Chem. Bull. 2002, 51, 503–505. [Google Scholar] [CrossRef]
  90. Connor, D.T. 1,5-Dihydro-1,5-dioxo-N-1H-tetrazol-5-yl-4H-[1]benzopyrano[3,4-b]pyridine-3-Carboxamides and Process Thereof. Patent US4198511A, 15 April 1980. [Google Scholar]
  91. Goerlitzer, K.; Kramer, C. Potenzielle Antiallergika: Darstellung und Reaktionen von 1,4-Dihydro-4-oxo-[1]benzofuro[3, 2-b]pyridin-2-carbonsäureestern. Pharmazie 2000, 8, 587–594. [Google Scholar]
  92. Fehér, E.; Szatmári, I.; Dudás, T.; Zalatnai, A.; Farkas, T.; Lőrinczi, B.; Fülöp, F.; Vécsei, L.; Toldi, J. Structural evaluation and electrophysiological effects of some kynurenic acid analogs. Molecules 2019, 24, 3502. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Hall, M.C.; Johnson, G.H.; Wright, B.J. Quinoline derivatives as antiallergy agents. J. Med. Chem. 1974, 17, 685–690. [Google Scholar] [CrossRef] [PubMed]
  94. Bryant, J.A.; Buckman, B.O.; Islam, I.; Mohan, R.; Morrissey, M.M.; Wei, G.P.; Wei, X.; Yuan, S. Platelet Adenosine Diphosphate Receptor Antagonists. Patent US2003060474A1, 27 March 2003. [Google Scholar]
  95. Lőrinczi, B.; Csámpai, A.; Fülöp, F.; Szatmári, I. Synthetic-and DFT modelling studies on regioselective modified Mannich reactions of hydroxy-KYNA derivatives. RSC Adv. 2021, 11, 543. [Google Scholar] [CrossRef]
  96. Sloan, N.L.; Luthra, S.K.; McRobbie, G.; Pimlott, S.L.; Sutherland, A. Late stage iodination of biologically active agents using a one-pot process from aryl amines. RSC Adv. 2017, 7, 54881–54891. [Google Scholar] [CrossRef] [Green Version]
  97. Szatmári, I.; Fülöp, F. Syntheses, transformations and applications of aminonaphthol derivatives prepared via modified Mannich reactions. Tetrahedron 2013, 69, 1255–1278. [Google Scholar] [CrossRef] [Green Version]
  98. Szatmári, I.; Fülöp, F. Microwave-Assisted One-Pot Synthesis of (Aminoalkyl)naphthols and (Aminoalkyl)quinolinols by Using Ammonium Carbamate or Ammonium Hydrogen Carbonate as Solid Ammonia Source. Synthesis 2009, 5, 775–778. [Google Scholar] [CrossRef]
  99. Szatmári, I.; Fülöp, F. Simple access to pentacyclic oxazinoisoquinolines via an unexpected transformation of aminomethylnaphthols. Tetrahedron Lett. 2011, 52, 4440–4442. [Google Scholar] [CrossRef]
  100. Sas, J.; Szatmári, I.; Fülöp, F. C-3 functionalization of indole derivatives with isoquinolines. Curr. Org. Chem. 2016, 20, 2038–2054. [Google Scholar]
  101. Lőrinczi, B.; Csámpai, A.; Fülöp, F.; Szatmári, I. Synthesis of new C-3 substituted kynurenic acid derivatives. Molecules 2020, 25, 937. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Ijms 22 11935 g001 550
Figure 1. Structure of KYNA.
Figure 1. Structure of KYNA.
Ijms 22 11935 g001
Ijms 22 11935 g002 550
Figure 2. General formula for the Nitrogen-containing ring system.
Figure 2. General formula for the Nitrogen-containing ring system.
Ijms 22 11935 g002
Ijms 22 11935 sch001 550
Scheme 1. Synthesis of 1,5-naphthyridine derivatives 3a,b.
Scheme 1. Synthesis of 1,5-naphthyridine derivatives 3a,b.
Ijms 22 11935 sch001
Ijms 22 11935 sch002 550
Scheme 2. Synthesis of naphthyridine derivative 6 via acetophenone analog 4.
Scheme 2. Synthesis of naphthyridine derivative 6 via acetophenone analog 4.
Ijms 22 11935 sch002
Ijms 22 11935 sch003 550
Scheme 3. 1,7-Naphthyridine derivative with possible kinase-inhibiting effect.
Scheme 3. 1,7-Naphthyridine derivative with possible kinase-inhibiting effect.
Ijms 22 11935 sch003
Ijms 22 11935 sch004 550
Scheme 4. 1,7-Naphthyridine derivatives (10, 11, 13) with possible acetyl coenzyme A inhibiting effect.
Scheme 4. 1,7-Naphthyridine derivatives (10, 11, 13) with possible acetyl coenzyme A inhibiting effect.
Ijms 22 11935 sch004
Ijms 22 11935 sch005 550
Scheme 5. Synthesis of C-3 methyl-substituted 1,8-naphthyridine derivative 16.
Scheme 5. Synthesis of C-3 methyl-substituted 1,8-naphthyridine derivative 16.
Ijms 22 11935 sch005
Ijms 22 11935 sch006 550
Scheme 6. Proposed synthesis of 1,8-naphthyridine derivative 19.
Scheme 6. Proposed synthesis of 1,8-naphthyridine derivative 19.
Ijms 22 11935 sch006
Ijms 22 11935 sch007 550
Scheme 7. Synthesis of 1,8-naphthyridine derivative 19 and its use as a foldamer building block.
Scheme 7. Synthesis of 1,8-naphthyridine derivative 19 and its use as a foldamer building block.
Ijms 22 11935 sch007
Ijms 22 11935 sch008 550
Scheme 8. Synthesis of pyrrolidine substituted 1,8-naphthyridine 23.
Scheme 8. Synthesis of pyrrolidine substituted 1,8-naphthyridine 23.
Ijms 22 11935 sch008
Ijms 22 11935 sch009 550
Scheme 9. Synthesis of pyrido[3,2-d]pyrimidine derivative 26.
Scheme 9. Synthesis of pyrido[3,2-d]pyrimidine derivative 26.
Ijms 22 11935 sch009
Ijms 22 11935 sch010 550
Scheme 10. Possible methods for the synthesis of pyrido[2,3-d]pyrimidine derivative 31.
Scheme 10. Possible methods for the synthesis of pyrido[2,3-d]pyrimidine derivative 31.
Ijms 22 11935 sch010
Ijms 22 11935 sch011 550
Scheme 11. Synthesis of pyrido[2,3-d]pyrimidine derivatives 33a–g, 34a,b via acetophenone derivatives 32a–g.
Scheme 11. Synthesis of pyrido[2,3-d]pyrimidine derivatives 33a–g, 34a,b via acetophenone derivatives 32a–g.
Ijms 22 11935 sch011
Ijms 22 11935 sch012 550
Scheme 12. Synthesis of C-3 functionalized N-bridgehead derivative 36 using metal catalyst.
Scheme 12. Synthesis of C-3 functionalized N-bridgehead derivative 36 using metal catalyst.
Ijms 22 11935 sch012
Ijms 22 11935 sch013 550
Scheme 13. Metal-free synthesis of compound 36 and bromo-substituted derivative 38.
Scheme 13. Metal-free synthesis of compound 36 and bromo-substituted derivative 38.
Ijms 22 11935 sch013
Ijms 22 11935 sch014 550
Scheme 14. Synthesis of unsubstituted N-bridgehead derivative 40.
Scheme 14. Synthesis of unsubstituted N-bridgehead derivative 40.
Ijms 22 11935 sch014
Ijms 22 11935 sch015 550
Scheme 15. Synthesis of C-3 aryl- and alkoxy-substituted derivatives 43a–c.
Scheme 15. Synthesis of C-3 aryl- and alkoxy-substituted derivatives 43a–c.
Ijms 22 11935 sch015
Ijms 22 11935 sch016 550
Scheme 16. Synthesis of C-3 hydroxy-substituted N-bridgehead derivatives 45a,b.
Scheme 16. Synthesis of C-3 hydroxy-substituted N-bridgehead derivatives 45a,b.
Ijms 22 11935 sch016
Ijms 22 11935 sch017 550
Scheme 17. Synthesis of N-bridgehead KYNA derivative 48 via ring-member extension.
Scheme 17. Synthesis of N-bridgehead KYNA derivative 48 via ring-member extension.
Ijms 22 11935 sch017
Ijms 22 11935 sch018 550
Scheme 18. Synthesis of derivatives 36 and 51 via a manganese-catalyzed reaction.
Scheme 18. Synthesis of derivatives 36 and 51 via a manganese-catalyzed reaction.
Ijms 22 11935 sch018
Ijms 22 11935 sch019 550
Scheme 19. Synthesis of 40 from an azide starting compound.
Scheme 19. Synthesis of 40 from an azide starting compound.
Ijms 22 11935 sch019
Ijms 22 11935 sch020 550
Scheme 20. Further method for the synthesis of C-3 substituted N-bridgehead derivatives.
Scheme 20. Further method for the synthesis of C-3 substituted N-bridgehead derivatives.
Ijms 22 11935 sch020
Ijms 22 11935 sch021 550
Scheme 21. Pyrolytic decomposition of compound 59 yielding N-bridgehead derivative 61 of KYNA.
Scheme 21. Pyrolytic decomposition of compound 59 yielding N-bridgehead derivative 61 of KYNA.
Ijms 22 11935 sch021
Ijms 22 11935 sch022 550
Scheme 22. Synthesis of pyrimido[1,2-b]pyridazine derivative (64a) of KYNA.
Scheme 22. Synthesis of pyrimido[1,2-b]pyridazine derivative (64a) of KYNA.
Ijms 22 11935 sch022
Ijms 22 11935 sch023 550
Scheme 23. Synthesis of adenosine derivative 66.
Scheme 23. Synthesis of adenosine derivative 66.
Ijms 22 11935 sch023
Ijms 22 11935 sch024 550
Scheme 24. Synthesis of perimidine derivative 68.
Scheme 24. Synthesis of perimidine derivative 68.
Ijms 22 11935 sch024
Ijms 22 11935 sch025 550
Scheme 25. Synthesis of indole-fused N-bridgehead derivative 72a–e from azide starting compounds.
Scheme 25. Synthesis of indole-fused N-bridgehead derivative 72a–e from azide starting compounds.
Ijms 22 11935 sch025
Ijms 22 11935 sch026 550
Scheme 26. Synthesis of δ-carboline KYNA derivatives 76a–c.
Scheme 26. Synthesis of δ-carboline KYNA derivatives 76a–c.
Ijms 22 11935 sch026
Ijms 22 11935 sch027 550
Scheme 27. Synthesis of α-carboline KYNA derivative 79.
Scheme 27. Synthesis of α-carboline KYNA derivative 79.
Ijms 22 11935 sch027
Ijms 22 11935 sch028 550
Scheme 28. Synthesis of tetraphenylporphin derivatives 82a,b.
Scheme 28. Synthesis of tetraphenylporphin derivatives 82a,b.
Ijms 22 11935 sch028
Ijms 22 11935 g003 550
Figure 3. General formula for the Sulfur-containing ring system.
Figure 3. General formula for the Sulfur-containing ring system.
Ijms 22 11935 g003
Ijms 22 11935 sch029 550
Scheme 29. Synthesis of 10H-thiochromeno [3,2-b]pyridine derivatives 85a–c.
Scheme 29. Synthesis of 10H-thiochromeno [3,2-b]pyridine derivatives 85a–c.
Ijms 22 11935 sch029
Ijms 22 11935 sch030 550
Scheme 30. Synthesis of thiophene derivatives 88a,b, 92a,b and 93a,b.
Scheme 30. Synthesis of thiophene derivatives 88a,b, 92a,b and 93a,b.
Ijms 22 11935 sch030
Ijms 22 11935 sch031 550
Scheme 31. Synthesis of the thieno analog of δ-carboline derivative 76b.
Scheme 31. Synthesis of the thieno analog of δ-carboline derivative 76b.
Ijms 22 11935 sch031
Ijms 22 11935 sch032 550
Scheme 32. Synthesis of thieno[3,4-b]pyridine derivative 98.
Scheme 32. Synthesis of thieno[3,4-b]pyridine derivative 98.
Ijms 22 11935 sch032
Ijms 22 11935 g004 550
Figure 4. General formula for the Oxygen-containing ring system.
Figure 4. General formula for the Oxygen-containing ring system.
Ijms 22 11935 g004
Ijms 22 11935 sch033 550
Scheme 33. Synthesis of benzopyranopyridine derivatives 101a–c.
Scheme 33. Synthesis of benzopyranopyridine derivatives 101a–c.
Ijms 22 11935 sch033
Ijms 22 11935 sch034 550
Scheme 34. Synthesis of pyrano[4,3-b]pyridine compounds 103a–c via acetophenone derivatives.
Scheme 34. Synthesis of pyrano[4,3-b]pyridine compounds 103a–c via acetophenone derivatives.
Ijms 22 11935 sch034
Ijms 22 11935 sch035 550
Scheme 35. Synthesis of pyrano[3,4-b]pyridine derivatives 106a–c.
Scheme 35. Synthesis of pyrano[3,4-b]pyridine derivatives 106a–c.
Ijms 22 11935 sch035
Ijms 22 11935 sch036 550
Scheme 36. Synthesis of 108 the furan analog of δ-carboline 76b.
Scheme 36. Synthesis of 108 the furan analog of δ-carboline 76b.
Ijms 22 11935 sch036
Ijms 22 11935 sch037 550
Scheme 37. Synthesis of KYNA ethyl ester.
Scheme 37. Synthesis of KYNA ethyl ester.
Ijms 22 11935 sch037
Ijms 22 11935 sch038 550
Scheme 38. Synthesis of hydroxykynurenic acid derivatives.
Scheme 38. Synthesis of hydroxykynurenic acid derivatives.
Ijms 22 11935 sch038
Ijms 22 11935 sch039 550
Scheme 39. Synthesis of KYNA and B-ring substituted KYNA Mannich derivatives.
Scheme 39. Synthesis of KYNA and B-ring substituted KYNA Mannich derivatives.
Ijms 22 11935 sch039
Ijms 22 11935 g005 550
Figure 5. Structures of hydroxy-KYNA derivatives.
Figure 5. Structures of hydroxy-KYNA derivatives.
Ijms 22 11935 g005
Ijms 22 11935 sch040 550
Scheme 40. Aminoalkylations of the ethyl esters of 5- and 8-hydroxykynurenic acids. (i) 114c:morpholine:(CH2O)n 1:1:3; EtOH, MW, 150 °C, 1 h; (ii) 114c:morpholine:(CH2O)n 1:3:4.6; EtOH, MW, 80 °C, 2 h; (iii) 131:morpholine:(CH2O)n 1:1:3; dioxane, MW, 150 °C, 2 h; (iv) 131:morpholine:(CH2O)n 1:3:4.6; toluene, MW, 80 °C, 1 h.
Scheme 40. Aminoalkylations of the ethyl esters of 5- and 8-hydroxykynurenic acids. (i) 114c:morpholine:(CH2O)n 1:1:3; EtOH, MW, 150 °C, 1 h; (ii) 114c:morpholine:(CH2O)n 1:3:4.6; EtOH, MW, 80 °C, 2 h; (iii) 131:morpholine:(CH2O)n 1:1:3; dioxane, MW, 150 °C, 2 h; (iv) 131:morpholine:(CH2O)n 1:3:4.6; toluene, MW, 80 °C, 1 h.
Ijms 22 11935 sch040
Ijms 22 11935 sch041 550
Scheme 41. Morpholinomethylations of the ethyl esters of 6- and 7-hydroxykynurenic acids. (i) 114a:morpholine:(CH2O)n 1:3:4.6; EtOH, MW, 80 °C, 30 min; (ii) 114a:morpholine:(CH2O)n 1:3:4.6; EtOH, MW, 80 °C, 2 h; (iii) 114b:morpholine:(CH2O)n 1:1:3; EtOH, MW, 80 °C, 1.5 h; (iv) 114b:morpholine:(CH2O)n 1:2:4; EtOH, reflux, 56 h.
Scheme 41. Morpholinomethylations of the ethyl esters of 6- and 7-hydroxykynurenic acids. (i) 114a:morpholine:(CH2O)n 1:3:4.6; EtOH, MW, 80 °C, 30 min; (ii) 114a:morpholine:(CH2O)n 1:3:4.6; EtOH, MW, 80 °C, 2 h; (iii) 114b:morpholine:(CH2O)n 1:1:3; EtOH, MW, 80 °C, 1.5 h; (iv) 114b:morpholine:(CH2O)n 1:2:4; EtOH, reflux, 56 h.
Ijms 22 11935 sch041
Table
Table 1. Reaction conditions for the preparation of 1,5-naphthyridine derivatives.
Table 1. Reaction conditions for the preparation of 1,5-naphthyridine derivatives.
ReactionReagentSolventTemperature (°C)Reaction TimeYield (%)
idiethyl oxalacetateglacial acetic acid40–50 °C; r.t.4 h; overnight2a 43% [26]
neat90 °C7 h2b 21% [27]
sodium (Z)-1,4-diethoxy-1,4-dioxobut-2-en-2-olateglacial acetic acidr.t.2.5 days2b 23% [28]
ii-Ph2Oreflux10 + 10 min3a 84% [26]
Dowtherm A210 °C5 h3b 34% [27]
Ph2Oreflux15 + 20 min3b 29% [28]
Table
Table 2. KYNA Mannich derivatives.
Table 2. KYNA Mannich derivatives.
Compound #R2R3R4Yield (%)
118H2-morpholinoethylH78
119H2-(dimethylamino)ethylPh74
120MeMeH82
121MeBzH85
122morpholineH91
123piperidineH73
124N-methyl-piperazineH78
1251,2,3,4-tetrahydroisoquinolineH81
1266,7-dimethoxy-1,2,3,4-tetrahydroisoquinolineH72
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lőrinczi, B.; Szatmári, I. KYNA Derivatives with Modified Skeleton; Hydroxyquinolines with Potential Neuroprotective Effect. Int. J. Mol. Sci. 2021, 22, 11935. https://doi.org/10.3390/ijms222111935

AMA Style

Lőrinczi B, Szatmári I. KYNA Derivatives with Modified Skeleton; Hydroxyquinolines with Potential Neuroprotective Effect. International Journal of Molecular Sciences. 2021; 22(21):11935. https://doi.org/10.3390/ijms222111935

Chicago/Turabian Style

Lőrinczi, Bálint, and István Szatmári. 2021. "KYNA Derivatives with Modified Skeleton; Hydroxyquinolines with Potential Neuroprotective Effect" International Journal of Molecular Sciences 22, no. 21: 11935. https://doi.org/10.3390/ijms222111935

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop